Axelar Receives Financing For A Phase I/II Clinical Trial On Cancer Patients

June 12, 2008 - Stockholm, Sweden - Axelar AB today announced that the company has received financing from Östersjöstiftelsen (the Foundation for Baltic and East European Studies) and Karolinska Development AB to perform a Phase I/II clinical trial with the insulin-like growth  factor-1 (IGF-1) receptor inhibitor AXL1717 on cancer patients.

See PDF